Moreover, the enrichment of SP100 family members in diverse carcinogenic pathways and their close relationship with TP53 mutation status suggest potential mechanisms through which SP100 family members contribute to the initiation and progression of PAAD. This evidence concerns the gene SP100 and pancreatic adenocarcinoma.